- ChemoCentryx (NASDAQ:CCXI) +323% on positive test results.
- Nutanix (NASDAQ:NTNX) +18% on Q1 earnings.
- InflaRx N.V. (NASDAQ:IFRX) +11%.
- DICK'S Sporting Goods (NYSE:DKS) +11% on Q3 earnings, FY guidance.
- Global Blood Therapeutics (NASDAQ:GBT) +11% on FDA approval of Oxbryta.
- BlueLinx Holdings (NYSE:BXC) +10% on deleveraging initiatives.
- Editas Medicine (NASDAQ:EDIT) +10%.
- Bio-Path Holdings (NASDAQ:BPTH) +7% on completing safety testing in Phase 2 trial in Acute Myeloid Leukemia.
- Taronis Technologies (NASDAQ:TRNX) +6%.
- SELLAS Life Sciences Group (NASDAQ:SLS) +5%.
- Mallinckrodt (NYSE:MNK) +5% on updating Acthar Gel study.
- Sunworks (NASDAQ:SUNW) +5% on receiving approval to commence construction of a public works project in Northern California.